Hims & Hers Health announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers’ first international generic GLP-1 offering. Personalized treatment plans are available starting at $149 CAD/month.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers Plans $300M Convertible Notes for Expansion
- Hims & Hers price target lowered to $28 from $30 at BofA
- Morning News Wrap-Up, 5/18/26: Today’s Biggest Stock Market Stories!
- Here’s Why Hims & Hers Stock Tumbled 9% Today, 5/18/26
- Hims & Hers announces proposed convertible senior notes offering